Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Susan O’Brien, Richard R. Furman et al.|New England Journal of Medicine|2013Cited by 2.2k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H. Wilson, Louis M. Staudt, Vaishalee P. Kenkre et al.|Nature Medicine|2015Cited by 1.1k
A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.Samantha Jaglowski, John C. Byrd, Jeffrey A. Jones et al.|Journal of Clinical Oncology|2012Cited by 65
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Chaitra S. Ujjani, Bruce D. Cheson, Sin‐Ho Jung et al.|Blood|2016Cited by 59
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II StudySusan O’Brien, John C. Byrd, Jan A. Burger et al.|Blood|2011Cited by 56